Oncogenic Mutations of PIK3CA in Human Cancers

Overview

Journal Curr Top Microbiol Immunol

Specialties Allergy & Immunology
Microbiology

Date 2010 Jun 11

PMID 20535651

Citations 135

Authors

Yardena Samuels

Todd Waldman

Affiliations

Soon will be listed here.

Abstract

The involvement of the PIK3CA gene product p110α, the catalytic subunit of phosphatidylinositol 3-kinase (PI3K), in human cancer has been suggested for over 15 years, and support for this proposal had been provided by both genetic and functional studies, including most recently the discovery of common activating missense mutations of PIK3CA in a wide variety of common human tumor types. This chapter will focus on the discovery of these mutations and describes their relevance to a wide range of common human tumor types.Of note, the identification and functional analysis of the PIK3CA gene are reviewed in other chapters in this book. However, a brief mention will be made here of its general properties as background to our focus on the discovery of its cancer-specific mutations.

Citing Articles

Discovery of a selective PI3Kα inhibitor structure-based virtual screening for targeted colorectal cancer therapy.

Albassam H, Almutairi O, Alnasser M, Altowairqi F, Almutairi F, Alobid S J Enzyme Inhib Med Chem. 2025; 40(1):2468852.

PMID: 39992303 PMC: 11852364. DOI: 10.1080/14756366.2025.2468852.

De-regulation of aurora kinases by oncogenic HPV; implications in cancer development and treatment.

Oladipo K, Parish J Tumour Virus Res. 2025; 19:200314.

PMID: 39923999 PMC: 11867274. DOI: 10.1016/j.tvr.2025.200314.

Correlation Between PIK3R1 Expression and Cell Growth in Human Breast Cancer Cell Line BT-474 and Clinical Outcomes.

Tsai Y, Lai J, Liu C, Hsi C, Hsu C, Huang C World J Oncol. 2025; 16(1):131-141.

PMID: 39850525 PMC: 11750754. DOI: 10.14740/wjon1986.

Non-coding RNAs and regulation of the PI3K signaling pathway in lung cancer: Recent insights and potential clinical applications.

Hashemi M, Abolghasemi Fard A, Pakshad B, Asheghabadi P, Hosseinkhani A, Hosseini A Noncoding RNA Res. 2024; 11:1-21.

PMID: 39720352 PMC: 11665378. DOI: 10.1016/j.ncrna.2024.11.006.

Direct comparison of an ultrasensitive real-time PCR assay with droplet digital PCR for the detection of hotspot mutations in primary tumors, plasma cell-free DNA and paired CTC-derived gDNAs.

Smilkou S, Kaklamanis L, Balgouranidou I, Linardou H, Papatheodoridi A, Zagouri F Front Oncol. 2024; 14:1435559.

PMID: 39711963 PMC: 11659196. DOI: 10.3389/fonc.2024.1435559.

References

Or Y, Hui A, To K, Lam C, Lo K . PIK3CA mutations in nasopharyngeal carcinoma. Int J Cancer. 2005; 118(4):1065-7. DOI: 10.1002/ijc.21444. View

Staal S . Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci U S A. 1987; 84(14):5034-7. PMC: 305241. DOI: 10.1073/pnas.84.14.5034. View

Wu G, Xing M, Mambo E, Huang X, Liu J, Guo Z . Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res. 2005; 7(5):R609-16. PMC: 1242128. DOI: 10.1186/bcr1262. View

Ollikainen M, Gylling A, Puputti M, Nupponen N, Abdel-Rahman W, Butzow R . Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. Int J Cancer. 2007; 121(4):915-20. DOI: 10.1002/ijc.22768. View

Bellacosa A, De Feo D, Godwin A, BELL D, Cheng J, Altomare D . Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer. 1995; 64(4):280-5. DOI: 10.1002/ijc.2910640412. View

Miyake T, Yoshino K, Enomoto T, Takata T, Ugaki H, Kim A . PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences. Cancer Lett. 2008; 261(1):120-6. DOI: 10.1016/j.canlet.2007.11.004. View

Catasus L, Gallardo A, Cuatrecasas M, Prat J . PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod Pathol. 2007; 21(2):131-9. DOI: 10.1038/modpathol.3800992. View

Kim J, Lee C, Bonifant C, Ressom H, Waldman T . Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA. Mol Cell Biol. 2006; 27(2):662-77. PMC: 1800819. DOI: 10.1128/MCB.00537-06. View

Shayesteh L, Lu Y, Kuo W, Baldocchi R, Godfrey T, Collins C . PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 1999; 21(1):99-102. DOI: 10.1038/5042. View

10.

Cheng J, Godwin A, Bellacosa A, Taguchi T, Franke T, Hamilton T . AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A. 1992; 89(19):9267-71. PMC: 50107. DOI: 10.1073/pnas.89.19.9267. View

11.

Kozaki K, Imoto I, Pimkhaokham A, Hasegawa S, Tsuda H, Omura K . PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma. Cancer Sci. 2006; 97(12):1351-8. PMC: 11160012. DOI: 10.1111/j.1349-7006.2006.00343.x. View

12.

Thompson F, Emerson J, Olson S, Weinstein R, Leavitt S, Leong S . Cytogenetics of 158 patients with regional or disseminated melanoma. Subset analysis of near-diploid and simple karyotypes. Cancer Genet Cytogenet. 1995; 83(2):93-104. DOI: 10.1016/0165-4608(95)00057-v. View

13.

Bos J, Fearon E, Hamilton S, Verlaan-de Vries M, VAN Boom J, Van Der Eb A . Prevalence of ras gene mutations in human colorectal cancers. Nature. 1987; 327(6120):293-7. DOI: 10.1038/327293a0. View

14.

Qiu W, Tong G, Manolidis S, Close L, Assaad A, Su G . Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer. Int J Cancer. 2007; 122(5):1189-94. PMC: 2792983. DOI: 10.1002/ijc.23217. View

15.

Jhawer M, Goel S, Wilson A, Montagna C, Ling Y, Byun D . PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res. 2008; 68(6):1953-61. PMC: 3972216. DOI: 10.1158/0008-5472.CAN-07-5659. View

16.

Bastian B, Leboit P, Hamm H, Brocker E, Pinkel D . Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res. 1998; 58(10):2170-5. View

17.

Sparks A, Morin P, Vogelstein B, Kinzler K . Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 1998; 58(6):1130-4. View

18.

Wu G, Mambo E, Guo Z, Hu S, Huang X, Gollin S . Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab. 2005; 90(8):4688-93. DOI: 10.1210/jc.2004-2281. View

19.

Abubaker J, Bavi P, Al-Harbi S, Ibrahim M, Siraj A, Al-Sanea N . Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene. 2008; 27(25):3539-45. DOI: 10.1038/sj.onc.1211013. View

20.

Wang Y, Helland A, Holm R, Kristensen G, Borresen-Dale A . PIK3CA mutations in advanced ovarian carcinomas. Hum Mutat. 2005; 25(3):322. DOI: 10.1002/humu.9316. View